午夜插插,噜噜噜影院,啪啪伊人网,欧美熟夫,景甜吻戏视频,男人强操性感蕾丝美女视频在线网站,日本美女跳舞视频

Welcome to chemicalbook!
+1 (818) 612-2111
Inquriy
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

RFQ
skype
MY Account
Top
Postion:Product Catalog >Biochemical Engineering>Inhibitors>Retatrutide
Retatrutide
  • Retatrutide

Retatrutide

Price Get Latest Price
Package 15mg 30mg
Min. Order: 15mg
Supply Ability: 5000box
Update Time: 2025-03-12

Product Details

Product Name: Retatrutide CAS No.: 2381089-83-2
Min. Order: 15mg Purity: 99%
Supply Ability: 5000box Release date: 2025/03/12

?Retatrutide (LY3437943) | GIP/GLP-1/GCGR Triple Agonist Peptide?
?? ?Product Overview?
Retatrutide is a novel ?triple agonist peptide? targeting GIP, GLP-1, and GCGR receptors, designed to regulate glucose metabolism and promote weight loss. It combines the therapeutic benefits of incretin hormones and glucagon activity, making it a breakthrough in metabolic disorder treatment. Primary applications include ?obesity management? and ?type 2 diabetes therapy? with enhanced efficacy compared to single-target agents?15.


?? ?Key Advantages?
?Triple-Action Mechanism?: Simultaneously activates GIP, GLP-1, and GCGR receptors for synergistic metabolic effects.
?High Efficacy?: Clinical trials show ?≥15% weight reduction? in obese patients and ?HbA1c reduction by 1.5-2.0%? in diabetics?15.
?Extended Half-Life?: Engineered peptide structure ensures prolonged activity with once-weekly dosing.


?? ?Application Areas?

  • ?Obesity Treatment?: Reduces appetite and enhances energy expenditure.

  • ?Type 2 Diabetes?: Improves glycemic control and insulin sensitivity.

  • ?Cardiometabolic Health?: Potential benefits in NAFLD (non-alcoholic fatty liver disease) and cardiovascular risk reduction?.


?? ?Quality & Compliance?

  • ?HPLC purity ≥98%?.

  • Compliant with ?USP/EP standards? for peptide synthesis and stability testing.


?? ?Market Trends?
The global ?anti-obesity drug market? is projected to reach ?$54.8 billion by 2030? (CAGR 14.2%), driven by rising obesity rates and demand for multi-target therapies. Retatrutide’s triple-action profile positions it as a leader in next-generation metabolic treatments?5.

Article illustration

Article illustration

Article illustration

Article illustration


Company Profile Introduction

Wuhan Biocar Pharmaceutical Co., Ltd. is a high-tech and innovative enterprise specializing in the research, development, production, and sales of APIs and pharmaceutical intermediates (excluding finished drugs). Located in the heart of Optics Valley Biological City, our company leverages the cutting-edge facilities of the Wuhan University Scientific Research Laboratory and benefits from the region's favorable policies to advance the field of biomedicine. Guided by our business philosophy—"Driven by market demand, powered by technological innovation, and enabled by e-commerce"—we are committed to delivering biomedical products that are precise, high-quality, fast, and reliable. Our offerings serve pharmaceutical companies, university research institutions, hospital outpatient services, reagent providers, and distributors worldwide.

You may like

Recommended supplier

Product name Price   Suppliers Update time
$27.00/1Box
VIP1Y
American HealthyMorph LLC
2025-03-10
$5.00/1mg
VIP1Y
Hebei Mujin Biotechnology Co.,Ltd
2025-03-07
$0.00/25KG
VIP5Y
Hebei Mujin Biotechnology Co.,Ltd
2025-03-06
$20.00/1g
VIP3Y
GIHI CHEMICALS CO.,LIMITED
2025-02-12
$0.00/1g
VIP1Y
Wuhan Circle Star Chem-medical Technology Co.,Ltd
2025-01-22
$5.00/1box
VIP1Y
Hebei Jiafan Trading Company Limited
2025-01-08
$130.00/10BOX
VIP1Y
Hebei Shengyang Water Conservancy Engineering Co., Ltd.
2025-01-06
$0.00/1g
VIP1Y
Zhangzhou Sinobioway Peptide Co.,Ltd.
2024-12-17
$20.00/1kg
Shaanxi Franta Biotechnology Co., Ltd
2024-12-06
$60.00/1Box
Hebei Weimiao Import and Export Trade Co., Ltd.
2024-11-12
  • Since: 2018-06-08
  • Address: Biolake.858 high-tech avenue,Wuhan
INQUIRY

+86-+undefined-+86 13343427080
sales@biocarchem.com